# Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

> **NCT02658916** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 47 (actual)

## Conditions studied

- Supranuclear Palsy, Progressive

## Interventions

- **DRUG:** BIIB092

## Key facts

- **NCT ID:** NCT02658916
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-22
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** 251PP301(NCT03068468) primary endpoint was not met;further development of Gosuranemab BIIB092 in progressive supranuclear palsy will not be pursued.
- **Last updated:** 2020-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658916, "Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02658916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*